Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations
Franziska Niehr(University of California, Los Angeles), Antoni Ribas(University of California, Los Angeles)
Cited by 96
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
|New England Journal of Medicine|2016|3.1k
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
|Nature|2010|2.5k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
|Cell Reports|2017|1.9k